Powles Highlights “Transformative” Benefit of EV Plus Pembro While Sharing Long-Term Data for EV-302
The lead investigator for EV-302 said not long ago, survival of 12 to 14 months in this type of bladder cancer was considered ...
First-line treatment with enfortumab vedotin and pembrolizumab provides durable benefits over chemotherapy in advanced urothelial carcinoma.
Positve overall survival data could lead to a label expansion for Pfizer's combination to treat metastatic ...
Nuvation has a best-in-class lung cancer drug that could be approved in the US in June. Read why I'm bullish on the stock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results